[go: up one dir, main page]

WO1992001718A3 - Peptides fonctionnellement actifs derives de la selectine et ligand pour selectine gmp 140 - Google Patents

Peptides fonctionnellement actifs derives de la selectine et ligand pour selectine gmp 140 Download PDF

Info

Publication number
WO1992001718A3
WO1992001718A3 PCT/US1991/005059 US9105059W WO9201718A3 WO 1992001718 A3 WO1992001718 A3 WO 1992001718A3 US 9105059 W US9105059 W US 9105059W WO 9201718 A3 WO9201718 A3 WO 9201718A3
Authority
WO
WIPO (PCT)
Prior art keywords
gmp
sialyated
ligand
peptides
functionally active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/005059
Other languages
English (en)
Other versions
WO1992001718A2 (fr
Inventor
Rodger P Mcever
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oklahoma
Original Assignee
University of Oklahoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Oklahoma filed Critical University of Oklahoma
Priority to CA002086323A priority Critical patent/CA2086323C/fr
Priority to AU86207/91A priority patent/AU660627B2/en
Publication of WO1992001718A2 publication Critical patent/WO1992001718A2/fr
Publication of WO1992001718A3 publication Critical patent/WO1992001718A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

On a découvert que des peptides dérivés des 3 régions de la régions de la GMP-140 se liant à la lectine entrent en intéraction sélective avec les '' sélectines'' tel que la GMP-140, l'ELAM-1 et le récepteur de nostocytose lymphocytaire. Ces 3 régions contiennent des acides aminés 19-34, 54-72 et 66-89, numérotés sur la base des numéros des restes d'acides aminés contenus dans le peptide, le reste 1 étant défini comme la terminaison N de la protéine mature après clivage du peptide signal. Des structures de lactosamines à sialyle fucosylées qui se lient à la GMP-140 ont également été découvertes. Une telle structure est créée par l'expression de α(1,3) fucosyltranférases capables de modifier les accepteurs contenant des lactosaminoglycanes substitués par acide α(2,3) sialique. L'élément Lex, Galβ1,4(Fucα1,3)GLcNAcβ1-R (où R représente une protéine ou toute autre structure à hydrate de carbone) forme le noyau de cette structure à sialyle. Ces peptides et ces structures d'hydrates de carbone sont utiles comme agents de diagnostique et dans des applications cliniques de modulation ou d'inhibition des processus de coagulation ou des processus inflammatoires.
PCT/US1991/005059 1990-07-17 1991-07-17 Peptides fonctionnellement actifs derives de la selectine et ligand pour selectine gmp 140 Ceased WO1992001718A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002086323A CA2086323C (fr) 1990-07-17 1991-07-17 Peptides derives de la selectine actifs sur le plan fonctionnel et ligand pour gmp-140
AU86207/91A AU660627B2 (en) 1990-07-17 1991-07-17 Functionally active selectin-derived peptide for GMP-140

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55419990A 1990-07-17 1990-07-17
US554,199 1990-07-17
US65048491A 1991-02-05 1991-02-05
US650,484 1991-02-05

Publications (2)

Publication Number Publication Date
WO1992001718A2 WO1992001718A2 (fr) 1992-02-06
WO1992001718A3 true WO1992001718A3 (fr) 1992-05-14

Family

ID=27070521

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/005059 Ceased WO1992001718A2 (fr) 1990-07-17 1991-07-17 Peptides fonctionnellement actifs derives de la selectine et ligand pour selectine gmp 140

Country Status (9)

Country Link
EP (2) EP0544815A1 (fr)
JP (5) JP3096305B2 (fr)
AT (1) ATE224911T1 (fr)
AU (2) AU660627B2 (fr)
CA (1) CA2086323C (fr)
DE (1) DE69133120T2 (fr)
DK (1) DK0714912T3 (fr)
ES (1) ES2183851T3 (fr)
WO (1) WO1992001718A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060685B2 (en) 2002-05-16 2006-06-13 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
US7361644B2 (en) 2003-11-19 2008-04-22 Glycomimetics, Inc. Specific antagonist for both E- and P-selectins
US7517980B2 (en) 2005-08-09 2009-04-14 Glycomimetics, Inc. Glycomimetric inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from Pseudomonas
USRE44778E1 (en) 2005-09-02 2014-02-25 Glycomimetics, Inc. Heterobifunctional pan-selectin inhibitors
US8895510B2 (en) 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
US9109002B2 (en) 2011-12-22 2015-08-18 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) * 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
JPH05504470A (ja) * 1989-10-20 1993-07-15 ニューイングランド・メディカル・センター・ホスピタルズ・インコーポレーテッド Ｐａｄｇｅｍを介した細胞結合の阻害
US6391857B1 (en) 1990-06-18 2002-05-21 Stanford University Methods and compositions for endothelial binding
US6387884B1 (en) 1990-06-18 2002-05-14 Stanford University Leukocyte homing modulation
NZ240316A (en) * 1990-10-25 1996-12-20 Univ Michigan Compound for treating disease mediated by the elaboration of elam-1 on endothelial cells
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5807745A (en) * 1991-03-11 1998-09-15 New England Medical Center Hospitals, Inc. Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component
US6121233A (en) * 1991-04-19 2000-09-19 John L. Magnani Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
AU1926692A (en) * 1991-04-19 1992-11-17 Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for endothelial binding
EP0668871A1 (fr) * 1991-05-03 1995-08-30 The Rockefeller University Homologies au niveau de la sequence en acides amines entre les selectines et la toxine de b. pertussis-peptides en derivant et anticorps contre ces peptides et compositions pharmaceutiques
CA2103139A1 (fr) * 1991-05-14 1992-11-15 George A. Heavner Inhibiteurs peptidiques de l'inflammation
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
WO1993005070A1 (fr) * 1991-09-10 1993-03-18 Centocor, Inc. Inhibiteurs peptidiques des inflammations vehiculees par les selectines
WO1993005803A1 (fr) * 1991-09-25 1993-04-01 Genetics Institute, Inc. Agents anti-inflammatoires inhibiteurs de selectines
AU3914393A (en) * 1991-12-18 1994-03-15 Board Of Regents Of The University Of Oklahoma, The Peptide inhibitors of inflammation mediated by selectins
EP0639224B1 (fr) * 1992-04-30 2000-06-28 Genentech, Inc. Variants du domaine lectine de la selectine
CA2135083C (fr) * 1992-05-05 2004-01-06 Robert W. Chestnut Anticorps de la p-selectine et leur utilite
US6033667A (en) * 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
JPH07507302A (ja) * 1992-05-28 1995-08-10 セントコー・インコーポレーテッド セレクチン結合のペプチド阻害剤
WO1993024527A1 (fr) * 1992-05-28 1993-12-09 Centocor, Inc. Peptides inhibiteurs de la liaison de selectine
US5440015A (en) * 1992-07-21 1995-08-08 Glycomed Incorporated Selectin peptide medicaments for treating disease
US5753617A (en) * 1992-09-08 1998-05-19 Centocor, Inc. Peptide inhibitors of cellular adhesion
CA2145881C (fr) 1992-10-02 2000-12-19 Richard Smith Propriete anti-inflammatoire, pouvoir immuno-inhibant et tolerabilite des peptides liant les glucides
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
DK1396542T3 (da) * 1992-10-23 2011-06-06 Genetics Inst Llc P-selectin ligand protein
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
CA2151142C (fr) * 1992-11-16 2001-10-02 Richard D. Cummings Ligand glycoproteique pour la p-selectine et ses modes d'utilisation
WO1994014836A1 (fr) * 1992-12-18 1994-07-07 Centocor, Inc. Inhibiteurs peptidiques de liaison de selectine
WO1994026786A1 (fr) 1993-05-17 1994-11-24 T Cell Sciences, Inc. Compositions comprenant des proteines et des glucides apparentes complementaires, et leurs procedes de production et utilisation de ces compositions
US5856300A (en) * 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5976540A (en) * 1993-05-17 1999-11-02 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5750508A (en) * 1993-06-16 1998-05-12 Glycomed Incorporated Sialic acid/fucose based medicaments
WO1995014787A1 (fr) * 1993-11-22 1995-06-01 Centocor, Inc. Peptides inhibiteurs de liaison a la selectine
US5663151A (en) * 1994-03-04 1997-09-02 Bristol-Myers Squibb Company Sulfated α-glycolipid derivatives as cell adhesion inhibitors
CA2142153A1 (fr) * 1994-03-04 1995-09-05 Jacques Banville Derives .beta.-glycolipidiques sulfates, inhibiteurs de l'adherence cellulaire
AU2361395A (en) * 1994-04-28 1995-11-29 Genetics Institute Inc. Novel P-selectin ligand protein
US5686426A (en) * 1994-11-17 1997-11-11 Bristol-Myers Squibb Company Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
EP0833650A4 (fr) * 1995-06-14 2005-01-19 Gen Hospital Corp Ligands de p-selectine et procedes et molecules associes---
US5747463A (en) * 1995-11-13 1998-05-05 Bristol-Myers Squibb Company Malonate derivatives of glycolipids as cell adhesion inhibitors
WO1997047646A1 (fr) 1996-06-10 1997-12-18 Boren Thomas Adhesine d'helicobacter pylori se fixant a un antigene de groupe sanguin
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
SI1783222T1 (en) 1998-10-23 2012-09-28 Kirin Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity.
CA2572765C (fr) 2004-07-08 2013-05-21 Amgen Inc. Peptides therapeutiques
EP1797127B1 (fr) 2004-09-24 2017-06-14 Amgen Inc. Molecules fc modifiees
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
AU2013355238B2 (en) 2012-12-07 2017-12-14 Glycomimetics, Inc. Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
EP3227310B1 (fr) 2014-12-03 2019-07-31 GlycoMimetics, Inc. Inhibiteurs hétérobifonctionnels des e-sélectines et des récepteurs aux chimiokines cxcr4
CA3009836A1 (fr) 2016-01-22 2017-07-27 Glycomimetics, Inc. Inhibiteurs glycomimetiques des lectines pa-il et pa-iil
WO2017151708A1 (fr) 2016-03-02 2017-09-08 Glycomimetics, Inc. Méthodes pour le traitement et/ou à la prévention de maladies cardiovasculaires par inhibition de la sélectine e
EP3497131B1 (fr) 2016-08-08 2022-03-09 GlycoMimetics, Inc. Combinaison d'inhibiteurs des points de contrôle des lymphocytes t avec des inhibiteurs de e-sélectine ou de cxcr4, ou avec des inhibiteurs hétérobifonctionnels de e-sélectine et de cxcr4
CA3037850A1 (fr) 2016-10-07 2018-04-12 Glycomimetics, Inc. Antagonistes de e-selectine multimeriques tres puissants
KR20230132603A (ko) 2017-01-11 2023-09-15 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
CA3054067A1 (fr) 2017-03-14 2018-09-20 Five Prime Therapeutics, Inc. Anticorps se liant a vista a un ph acide
US11197877B2 (en) 2017-03-15 2021-12-14 Glycomimetics. Inc. Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists
WO2019108750A1 (fr) 2017-11-30 2019-06-06 Glycomimetics, Inc. Méthodes de mobilisation de lymphocytes infiltrant la moelle et leurs utilisations
CN111566117A (zh) 2017-12-29 2020-08-21 糖模拟物有限公司 E-选择蛋白和半乳凝素-3的异双功能抑制剂
CA3091454A1 (fr) 2018-03-05 2019-09-12 Glycomimetics, Inc. Methodes de traitement de la leucemie aigue myeloide et d'etats pathologiques associes
PE20210290A1 (es) 2018-03-21 2021-02-11 Five Prime Therapeutics Inc ANTICUERPOS DE UNION A VISTA A pH ACIDO
WO2020014327A2 (fr) 2018-07-11 2020-01-16 Five Prime Therapeutics, Inc. Anticorps se liant à vista à un ph acide
US20230310453A1 (en) * 2020-07-20 2023-10-05 Insmed, Inc. Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783330A (en) * 1984-11-15 1988-11-08 New England Medical Center Hospitals, Inc. Monoclonal antibodies to activated platelets
WO1991006632A1 (fr) * 1989-10-20 1991-05-16 New England Medical Center Hospitals, Inc. Inhibition de la liaison des cellules a mediation par padgem

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
US4792525A (en) 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4629784A (en) 1983-08-16 1986-12-16 The University Of Georgia Research Foundation, Inc. Synthesis of cyclopropane amino acids
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
AU610083B2 (en) 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5030723A (en) * 1988-05-31 1991-07-09 The Biomembrane Institute Long-chain glycolipid structure

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783330A (en) * 1984-11-15 1988-11-08 New England Medical Center Hospitals, Inc. Monoclonal antibodies to activated platelets
WO1991006632A1 (fr) * 1989-10-20 1991-05-16 New England Medical Center Hospitals, Inc. Inhibition de la liaison des cellules a mediation par padgem

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
AM.J.RESPIR.CELL MOL.BIOL., Vol. 3, 1990 S D. Rosen: "The LEC-CAMs: An Emerging Family of Cell Adhesion Receptors Based upon Carbohydrate Recognition ", see pages 397-402, especially page 401 *
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 164, No. 3, 1989 M P. Skinner et al: "Characterization of human platelet GMP-140 as a heparin-binding protein ", see pages 1373-1379, especially table 1 *
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 172, No. 3, 1990 L Corral et al: "Requirement for sialic acid on neutrophils in a GMP-140(PADGEM) mediated adhesive interaction with activated platelets ", see pages 1349-1356, especially page 1352 and "Discussion" *
BLOOD CELLS, Vol. 16, 1990 Rodger P. McEver: "Properties of GMP-140, an Inducible Granule Membrane Protein of Platelets and Endothelium ", see pages 73-83 *
CELL, Vol. 56, 1989 G I. Johnston et al: "Cloning of GMP-140, a Granule Membrane Protein of Platelets and Endothelium: Sequence Similarity to Proteins Involved in Cell Adhesion and Inflammation ", see pages 1033-1044, in particular figure 4 and page 1039 *
CELL, Vol. 59, 1989 Eric Larsen et al: "PADGEM Protein: A Receptor That Mediates the Interaction of Activated Platelets with Neutrophils and Monocytes ", see pages 305-312 *
CELL, Vol. 63, 1990 B K. Brandley: "Carbohydrate Ligands of the LEC Cell Adhesion Molecules ", see pages 861-863, especially page 862, right-hand column - page 863 *
CELL, Vol. 63, 1990 Eric Larsen et al: "PADGEM-Dependent Adhesion of Platelets to Monocytes and Neutrophils Is Mediated by a Lineage-Specific Carbohydrate, LNF III (CD15) ", see pages 467-474, especially page 469, right-hand column *
NATURE, Vol. 343, 1990 Jian-Guo Geng et al: "Rapid neutrophil adhesion to activated endothelium mediated by GMP-140 ", see pages 757-760 *
SCIENCE, Vol. 249, 1990 Jennifer R. Gamble et al: "Prevention of Activated Neutrophil Adhesion to Endothelium by Soluble Adhesion Protein GMP140 ", see pages 414-417 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 265, No. 14, 1990 David C. Ord et al: "Structure of the Gene Encoding the Human Leukocyte Adhesion Molecule-1(TQ1, Leu-8) of Lymphocytes and Neutrophils ", see pages 7760-7767, especially page 7760, right-hand column *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060685B2 (en) 2002-05-16 2006-06-13 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
US7361644B2 (en) 2003-11-19 2008-04-22 Glycomimetics, Inc. Specific antagonist for both E- and P-selectins
US7517980B2 (en) 2005-08-09 2009-04-14 Glycomimetics, Inc. Glycomimetric inhibitors of the PA-IL lectin, PA-IIL lectin or both the lectins from Pseudomonas
USRE44778E1 (en) 2005-09-02 2014-02-25 Glycomimetics, Inc. Heterobifunctional pan-selectin inhibitors
US8895510B2 (en) 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
US9534009B2 (en) 2008-04-08 2017-01-03 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
US9109002B2 (en) 2011-12-22 2015-08-18 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Also Published As

Publication number Publication date
JP3096305B2 (ja) 2000-10-10
DE69133120D1 (de) 2002-10-31
AU697488B2 (en) 1998-10-08
JP2004002444A (ja) 2004-01-08
JPH05509330A (ja) 1993-12-22
EP0544815A1 (fr) 1993-06-09
ES2183851T3 (es) 2003-04-01
JP2001197899A (ja) 2001-07-24
AU660627B2 (en) 1995-07-06
EP0714912B1 (fr) 2002-09-25
AU1773195A (en) 1995-07-06
AU8620791A (en) 1992-02-18
JP2005255691A (ja) 2005-09-22
EP0714912A3 (fr) 1996-06-26
DE69133120T2 (de) 2003-05-15
CA2086323C (fr) 2002-05-14
ATE224911T1 (de) 2002-10-15
WO1992001718A2 (fr) 1992-02-06
JPH11147900A (ja) 1999-06-02
CA2086323A1 (fr) 1992-01-18
DK0714912T3 (da) 2003-02-03
EP0714912A2 (fr) 1996-06-05

Similar Documents

Publication Publication Date Title
WO1992001718A3 (fr) Peptides fonctionnellement actifs derives de la selectine et ligand pour selectine gmp 140
Cantoni et al. p49, a putative HLA class I‐specific inhibitory NK receptor belonging to the immunoglobulin superfamily
Tanaka et al. Serine and threonine glycosidic linkages in bovine submaxillary mucin
Spiro et al. Structure of the O-glycosidically linked carbohydrate units of fetuin
Bird et al. Oligosaccharides containing fucose linked α (1–3) and α (1–4) to N-acetylglucosamine cause decompaction of mouse morulae
CA2290485A1 (fr) Procede de production de proteines non immunogenes
PT1672368E (pt) Epítopo de diagnóstico e terapêutico
CA2025598A1 (fr) Proteines d'antigene nucleocapsidique d'hepadnavirus chimerique
DE3787460D1 (de) Schimärische peptide für die lieferung von neuropeptiden durch die blut-hirn-grenze.
Hopsu-Havu et al. Formation of bradykinin from kallidin-10 by aminopeptidase B
GR3034352T3 (en) Novel polypeptides for promoting cell attachment.
NO924234D0 (no) Variant cd44-overflateproteiner, dna-sekvenser som koder for proteinene, antistoffer mot proteinene, samt anvendelser av proteinene i diagnose og terapi
Foltz et al. Purification and characterization of an extracellular fragment of the sea urchin egg receptor for sperm.
AU1342888A (en) Molecules comprising at least one peptidic sequence carrying one or a plurality of epitopes characterizing a protein produced by P.Falciparum in hepatocytes and compositions containing them
GR3030219T3 (en) LIVER-STAGE-SPECIFIC PEPTIDE SEQUENCES OF -i(P. FALCIPARUM) BEARING EPITOPES CAPABLE OF STIMULATING THE T LYMPHOCYTES
Dahr et al. SDS‐polyacrylamide gel electrophoretic analysis of the membrane glycoproteins from S‐s‐U‐erythrocytes
Rosse Paroxysmal nocturnal hemoglobinuria: the biochemical defects and the clinical syndrome
CA2080018A1 (fr) Nouveaux clones d'adnc de lymphomes t
EP0123928A3 (fr) ADN recombinant codant pour un polypeptide présentant une activité de coagulation du lait
EP1245575A3 (fr) Peptides fonctionellement actifs dérivés de sélectine et ligand pour GMP140
Butler et al. Dentin proteins: Chemistry, structure and biosynthesis
PIERCE et al. The chemistry of pituitary thyrotropin
EP1328290A2 (fr) Expression, preparation, utilisations et sequence de la proteine hla-g soluble derivee par recombinaison
ES2076933T3 (es) Nuevos sustratos peptidicos.
CA2006587A1 (fr) Proteines et peptides de membrane de haemophilus influenza de type b

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2086323

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991916882

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991916882

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991916882

Country of ref document: EP